TD Cowen raised the firm’s price target on Danaher to $290 from $280 and keeps a Buy rating on the shares. The firm said though the 2024 guide was largely maintained, they see a clear upside bias as the Bioproduction (BP) inflection is beginning, plus Dx and Life Sci also showed strength.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR: